Table 1 Demographic and clinical characteristics
From: Persistence with treatment for Wilson disease: a retrospective study
Variable, n = 170 | Values |
|---|---|
Male:female ratio, n (%) | 77 (45.3):93 (54.7) |
Age, mean ± SD (years) | 37.5 ± 10.4 |
Age at diagnosis, mean ± SD (years) | 25.0 ± 10.0 |
Time from symptom onset, mean ± SD (months) | 15.9 ± 14.2 |
Duration of treatment, mean ± SD (years) | 11.7 ± 3.2 |
Predominant clinical form at diagnosis, n (%) | |
Hepatic | 79 (46.5) |
Neurological | 91 (53.5) |
Type of initial treatment, n (%) | |
D-penicillamine | 98 (57.6) |
Zinc sulphate | 72 (42.4) |
Type of treatment during assessment, n (%) | |
D-penicillamine | 76 (44.7) |
Zinc sulphate | 94 (55.3) |
Persistence in drug use, n (%) | |
Yes | 126 (74.1) |
No | 44 (25.9) |
Adverse events, number of subjects (%) | 53 (31.2) |
Outcome of treatment (at the time of assessment), n (%) | |
Improvement | 38 (22.4) |
No change | 106 (62.4) |
Worsening | 26 (15.3) |